Loading
A phase 2/3 trial of Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, acute myeloid leukaemia and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Taiho Oncology, Inc., now recruiting.
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) is a phase 2/3 interventional study registered as NCT04256317 by Taiho Oncology, Inc., with 316 participants planned, started 2020-05-21 and due to reach its primary completion in 2027-11-01. Interventions recorded: Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine and Venetoclax.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.